Infant, Newborn
Conditions
Keywords
newborn, whole exome, genetic screening
Brief summary
The aim of the study is to obtain the initial experience of the inclusive genetic screening of newborn. Two groups of newborns born in RCOGP will be enlisted to the study: 1. newborns without developmental features having no variations according to an inherited diseases screening; 2. newborns showing either phenotypic features or deviations according to MS screening. The residual volume of the cord blood of all newborns form both groups will be collected and subjected to the whole exome sequencing. The sequencing data will be analyzed in screening mode for the first group while for the second group analysis will be performed taking the respective phenotype into account. The study is planned to cover 7000 newborns in total.
Interventions
GENETICScreening
Whole exome sequencing will be done and all infants will receive a report which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset diseases for which specific care or prevention protocols are available. Families signed additional informed consent will receive an advanced report including variants with no care or prevention available, mid or low risk variants, and variants with late onset or those suggesting relatives to undergo screening.
GENETICFamily history record
Families enrolled to the study will receive a genetic consult during which a family history will be taken concerning the inherited conditions.
OTHERQuestionnaire survey
Families invited to the study will be asked to undergo a questionnaire survey regarding the reasons to accept or refuse the study, the familiarity of the aims, methods and outcomes of the study as well as the satisfaction.
GENETICDiagnostic
The results of whole exome sequencing will be analysed according to the infant's phenotype in addition the the general screening pipeline
GENETICSelective screening
The results of whole exome sequencing will be analysed according to the data of prenatal ultrasound examination, family history and other available alarming information in addition the the general screening pipeline
Sponsors
Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Healthy volunteers
Yes
Inclusion criteria
Group 1 (newborns without features): Inclusion Criteria: * Infants born in the RCOGP, showing no development features and with no inherited diseases revealed by common screening * Informed consent signed by a newborn's representative
Exclusion criteria
* Parents refuse to participate * Parent(s) younger 18 years * Parent(s) unable to make decisions * The infant is older 30 d * Blood cannot be collected from the infant Group 2 (newborns with phenotypic features) Inclusion Criteria: * Infants showing either phenotypic features or deviations according to MS screening * Informed consent signed by a newborn's representative
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Estimate the frequency of revealing patients carrying genotype associated with a monogenic disese. | 3-5 months | The manifestation of pathogenic or likely pathogenic variants leading to a monogenic disease presenting during early age. A genotype is considered having risk of developping a monogenic disease in case pathogenic or probably pathogenic variants are detected corresponding to the inheritance model. |
| Phenotype-associated variants | 2 weeks - 2 months | Pathogenic, likely pathogenic variants or variants of uncertain significance corresponding to the observed clinical conditions |
| Motivations for refuse to participate | 1 day | Questionnaire answers provided by families refused to enroll |
| Acceptance of advanced screening | 1 day | Questionnaire answers provided by families accepted screening for variants of low penetrance, no care available etc. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Oncological risk | 1 day | Pathogenic or a likely pathogenic variant causing high risk of developping a cancer |
| Cardiological risk | 1 day | Pathogenic or a likely pathogenic variant causing high risk of developping a cardiomyopathy or a sudden cardiac death |
| Recessive carriers | 1 day | Inheritance of a pathogenic or a likely pathogenic variant causing to an autosomal recessive disease |
Countries
Russia
Contacts
Primary ContactJekaterina Shubina, PhD
Backup ContactAndrey A Bystritskiy, PhD
Outcome results
None listed